Quarterly report pursuant to Section 13 or 15(d)

Collaboration and Research Arrangements - Additional Information (Details)

v3.21.1
Collaboration and Research Arrangements - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended
Dec. 17, 2019
Jan. 08, 2018
Nov. 30, 2019
Jan. 31, 2018
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenue recognized         $ 4,827,000 $ 2,379,000  
Deferred revenue         19,952,000   $ 22,086,000
Deferred revenue, net of current portion         7,166,000   9,877,000
Global Blood Therapeutics              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Deferred revenue         15,396,000   16,721,000
Global Blood Therapeutics | Collaboration Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Initial period of research term 3 years            
Additional extension period for research term upon mutual agreement 1 year            
Upfront payment receivable $ 20,000,000.0            
Reimbursements receivable of full-time employee and out-of-pocket costs and expenses $ 40,000,000.0            
Agreement termination, prior written notice if notice delivered during the research term 9 months            
Agreement termination, prior written notice if notice delivered after the expiration or termination of the research term 90 days            
Total transaction price $ 60,000,000.0       60,000,000.0    
Upfront non-refundable and non-creditable payment 20,000,000.0            
Reimbursable costs $ 40,000,000.0            
Change in total transaction price         0    
Revenue recognized         4,000,000.0 2,200,000  
Deferred revenue         15,400,000    
Deferred revenue, short-term         8,800,000    
Deferred revenue, net of current portion         6,600,000    
Global Blood Therapeutics | Collaboration Agreement | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Period of extension of initial research term 2 years            
Receivable from option exercise, development, regulatory, commercialization and sales-based milestones per product candidate and product resulting $ 315,000,000.0            
Incyte              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenue recognized         800,000 200,000  
Deferred revenue         4,556,000   $ 5,365,000
Deferred revenue, short-term         4,000,000.0    
Deferred revenue, net of current portion         $ 600,000    
Incyte | Stock Purchase Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Aggregate purchase price       $ 10,000,000.0      
Shares issued       793,021      
Share price (in dollars per share)       $ 12.61      
Premium to volume-weighted sale price of shares (as a percent)       30.00%      
Trading days within which the purchase price represents a thirty percent (30%) premium to the volume-weighted sale price of the shares       15 days      
Incyte | Collaboration Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Total transaction price   $ 12,300,000 $ 12,800,000     12,800,000  
Upfront non-refundable and non-creditable payment           2,500,000  
Up-front consideration       $ 10,000,000.0      
Up-front consideration, cash       2,500,000      
Up-front consideration, pre-paid research funding       $ 7,500,000      
Prepaid research amount           7,500,000  
Premium paid on equity investment           2,300,000  
Collaboration agreement additional consideration incurred           $ 500,000